Immunotherapy, using a patient's own immune system to attack ... They specifically studied a subtype of melanoma triggered by a mutation of BRAF, a gene that helps regulate cell division. A mutation ...

Real-world data show that adjuvant therapy, not complete nodal dissection, is crucial for preventing relapse in patients with ...

The burden of low-grade toxicity is clinically significant in patients treated with adjuvant pembrolizumab for stage III melanoma.

Tafinlar/Mekinist are a blockbuster treatment regimen for BRAF-positive melanoma that ... insights into the role the investigational immunotherapy spartalizumab may play in future cancer therapy ...

A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled "GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells.

These medicines attack the BRAF protein and shrink or slow the growth of the cancer cells. If checkpoint inhibitors are not working, other immunotherapy drugs can include interleukin-2 or lifileucel.

LUAD is frequently associated with mutations in EGFR, KRAS, ALK, and BRAF, while LUSC is more commonly ... targeted therapies, and immunotherapy outcomes. For instance, pemetrexed-based ...